- Summits
- Sponsorship
- Retreats
- Media Opportunities
- News
- About
Hologic, Inc. has announced that its Chairman, President and Chief Executive Officer, Steve MacMillan, will retire upon the close of the company’s go-private transaction with Blackstone and TPG, marking the end of a leadership tenure that has spanned more than 12 years. The transaction is expected to close on or around April 7, 2026, following the receipt of all required regulatory approvals.
The announcement comes at a significant moment for the women’s health-focused medical technology company as it prepares to transition into private ownership. The deal, valued at approximately $18.3 billion, was first announced in 2025 and represents a major shift in Hologic’s next phase of growth.
“Hologic’s board of directors, and all the Company’s stakeholders, owe a debt of gratitude to Steve, one of the most respected leaders in the medical technology industry,” said Amy Wendell, Hologic’s lead independent director. “He forged a dramatic turnaround shortly after joining the Company, led us through years of consistent growth, drove our unprecedented response to the COVID pandemic, and is guiding us through a successful go-private transaction.”
MacMillan joined Hologic in December 2013 as President and CEO and was elected Chairman of the Board in 2015. During his tenure, the company reported a 65% increase in revenue, a 184% rise in non-GAAP earnings per share, and a 241% increase in share price. Over the same period, Hologic’s workforce grew by more than 1,500 employees.
Reflecting on his retirement, MacMillan described leading Hologic as “the greatest honor and privilege” of his career and expressed gratitude to the company’s customers, employees, board members, and investors.
He added that he remains confident in the company’s continued contribution to women’s health as it enters its next chapter under the ownership of Blackstone and TPG.
Before joining Hologic, MacMillan served as President and CEO of Stryker Corporation from 2005 to 2012, having previously held senior leadership roles at Johnson & Johnson and Pharmacia. He began his career at Procter & Gamble in 1985.
Hologic stated that its next CEO will be announced when the transaction officially closes.
As one of the leading medical technology companies focused on women’s health, Hologic has built its reputation on technologies for early detection, diagnostics, and treatment. The move to private ownership is expected to shape the company’s strategic direction in the years ahead.
Join the conversation at MedTech World North America 2026 | West Palm Beach, where global leaders, investors, innovators and healthcare decision-makers will come together to explore the developments influencing the MedTech industry. Be part of the dialogue driving meaningful progress across healthcare.
If you are looking to be part of this milestone flagship event, there are several ways to engage in line with your goals:
